Explanipedia

Association between cardiovascular-kidney-metabolic syndrome, inflammatory biomarkers, and cardiovascular outcomes: Insights from the MESA study Open

Muhammad Imtiaz Ahmad, Parag Anilkumar Chevli, Saeid Mirzai, Jared Spitz, Garima Sharma , et al. · 2025

These findings suggest that systemic inflammation, as measured by IL-6, may modify the risk of ASCVD and HF associated with CKM syndrome. Therefore, IL-6 measurement could potentially refine risk stratification and prognosis of CKM syndrom…

Cardiovascular disease risk estimates using the new PREVENT Equation: The good, bad, and the ugly Open

Pooja V. Selvam, Rahul Sharma, Peter Ganz, Roger S. Blumenthal, Martha Gulati · 2025

Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease Open

Alexander C. Razavi, Jing Chen, Wei Yang, Daohang Sha, Omar Dzaye , et al. · 2025

Calcified Versus Noncalcified Plaque in HIV Revisited Open

Alexander C. Razavi, Aaron L. Troy, Roger S. Blumenthal · 2025

LDL-cholesterol control in high-risk individuals: an international obstacle and call for earlier combination lipid-lowering therapy Open

Alexander C. Razavi, Mark Sokolsky, Roger S. Blumenthal · 2025

Prevalence and Correlates of Lipoprotein(a) Testing in a Diverse Cohort of U.S. Adults Open

Alexander C. Razavi, LaTonia C. Richardson, Fátima Coronado, Hubert W. Vesper, Alicia N. Lyle , et al. · 2025

The prevalence of Lp(a) testing among US adults is exceedingly low, especially for non-Hispanic Black individuals and those with socioeconomic risk. These results underline the importance of emphasizing health equity in Lp(a) testing expan…

High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure? Open

Adhya Mehta, Roger S. Blumenthal, Ty J. Gluckman, David Feldman, Payal Kohli · 2025

Inflammation and dyslipidemia are central to the pathogenesis of atherosclerotic cardiovascular disease (ASCVD). While lipid-lowering therapies are the cornerstone of ASCVD prevention and treatment, there are other emerging targets, includ…

2024: The Year in Cardiovascular Disease - The Year of Lipoprotein(a) – Research Advances and New Findings. Open

Bożena Sosnowska, Peter P. Tóth, Alexander C. Razavi, Alan T. Remaley, Roger S. Blumenthal , et al. · 2025

Elevated plasma Lp(a) levels, which occur in as many as 1.5 billion people worldwide, are an independent and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. Unlike low-density lipoprotein ch…

Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Case-Based Narrative Review Open

Aamir Javaid, Essa Hariri, Bige Özkan, Katherine Lang, Sadiya S. Khan , et al. · 2025

Epidemiology and Natural History of Preclinical and Clinical Obesity: Insights from the UK Biobank Open

Sohail Zahid, Jackie Yao, Sara M. Grimes, April Kim, Allison W. Peng , et al. · 2025

Association of Prepregnancy Cardiometabolic Health With Hypertensive Disorders of Pregnancy Among Historically Underrepresented Groups in the United States Open

Yaa A. Kwapong, Theresa Boyer, Oluwalonimi Adebowale, S. Michelle Ogunwole, Arthur J. Vaught , et al. · 2024

Background Prepregnancy diabetes and obesity are associated with hypertensive disorders of pregnancy (HDPs). However, the proportion of cases of HDP in the population explained by diabetes and obesity (population attributable fraction), es…

Digital health innovation and artificial intelligence in cardiovascular care: a case-based review Open

Jelani Grant, Aamir Javaid, Richard Carrick, Margaret Koester, Ali Asghar Kassamali , et al. · 2024

This narrative review aims to equip clinicians with an understanding of how digital health innovations and artificial intelligence can be applied to clinical care pathways for cardiovascular prevention. We describe a case that highlights a…

Coronary artery calcium density progression: Should we measure it? Open

Alexander C. Razavi, Roger S. Blumenthal, Mouaz H. Al‐Mallah, Mahmoud Al Rifai · 2024

Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk Open

Tarek Harb, Efthymios Ziogos, Roger S. Blumenthal, Gary Gerstenblith, Thorsten M. Leucker · 2024

Aims Lipoprotein(a) [Lp(a)] levels are predominantly genetically determined and repeat measurements are generally considered unlikely to be clinically useful. However, the temporal variation of Lp(a) is not well characterized. Our aim was …

Coronary Artery Calcium for Risk Stratification Among Persons With Very High HDL Cholesterol Open

Alexander C. Razavi, Anurag Mehta, Nathan D. Wong, Alan Rozanski, Matthew J. Budoff , et al. · 2024

Measurement of CAC may facilitate clinical risk assessment among individuals with very high HDL cholesterol.

Trends in Glucagon-Like Peptide-1 Receptor Agonist Social Media Posts Using Artificial Intelligence Open

Aamir Javaid, Sruthika Baviriseaty, Rehan Javaid, Ayah Zirikly, Harshita Kukreja , et al. · 2024

Neurocardiac Axis Physiology and Clinical Applications Open

Caroline Plott, Tarek Harb, Marios Arvanitis, Gary Gerstenblith, Roger S. Blumenthal , et al. · 2024

The neurocardiac axis constitutes the neuronal circuits between the arteries, heart, brain, and immune organs (including thymus, spleen, lymph nodes, and mucosal associated lymphoid tissue) that together form the cardiovascular brain circu…

Climate change and cardiovascular health: Recent updates and actions for healthcare Open

Jasmine K. Malhi, John W. McEvoy, Roger S. Blumenthal, Alan P. Jacobsen · 2024

Climate change is a public health crisis predominantly due to fossil fuel combustion, that challenges planetary and human health. Considerable evidence exists to demonstrate the impact climate change has on cardiovascular disease primarily…

COVID-19 in the Initiation and Progression of Atherosclerosis Open

Vignesh Chidambaram, Amudha Kumar, Murrium I. Sadaf, Emily Lu, Subhi J. Al’Aref , et al. · 2024

Ignoring Mental Well-Being Is Costing Lives Open

Roger S. Blumenthal, Adhya Mehta, Rishi Chandiramani · 2024

[Figure: see text]

Advances in predicting cardiovascular risk: Applying the PREVENT equations Open

Deen L. Garba, Alexander C. Razavi, Roger S. Blumenthal, Neil J. Stone, Tamar S. Polonsky , et al. · 2024

Testing practices and clinical management of lipoprotein(a) levels: A 5-year retrospective analysis from the Johns Hopkins Hospital Open

Yehuda Eidensohn, Anjali Bhatla, Jie Ding, Roger S. Blumenthal, Seth S. Martin , et al. · 2024

New Perspectives in Management of Cardiovascular Risk Among People With Diabetes Open

Abhishek Gami, Roger S. Blumenthal, Darren K. McGuire, Sudipa Sarkar, Payal Kohli · 2024

Following the publication of results from multiple landmark cardiovascular outcome trials of antihyperglycemic medications over the past 8 years, there has been a major shift in the focus of care for people with type 2 diabetes, from contr…

Design and rationale of the social determinants of the risk of hypertension in women of reproductive age (SAFE HEART) study: An American Heart Association research goes red initiative Open

Faith Metlock, Yaa A. Kwapong, Crystal Evans, Pamela Ouyang, Dhananjay Vaidya , et al. · 2024

Assessing athletes beyond routine screening: Incorporating essential factors to optimize cardiovascular health and performance Open

Deen L. Garba, Alan P. Jacobsen, Roger S. Blumenthal, Matthew W. Martinez, Chiadi E. Ndumele , et al. · 2024

The American Heart Association (AHA) has devised Life's Essential 8, a set of eight evidence-based health behaviors that play a crucial role in optimizing cardiovascular health and overall well-being. In addition to Life's Essential 8, enh…

Identifying People at High Risk for Severe Aortic Stenosis: Aortic Valve Calcium Versus Lipoprotein(a) and Low-Density Lipoprotein Cholesterol Open

Natalie Marrero, Kunal Jha, Alexander C. Razavi, Ellen Boakye, Khalil Anchouche , et al. · 2024

BACKGROUND: Aortic valve calcification (AVC), Lp(a) [lipoprotein(a)], and low-density lipoprotein cholesterol (LDL-C) are associated with severe aortic stenosis (AS). We aimed to determine which of these risk factors were most strongly ass…

The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease Open

Michael Khorsandi, Roger S. Blumenthal, Michael J. Blaha, Payal Kohli · 2024

Background The 2023 Multisociety Guideline for the Management of Chronic Coronary Disease (CCD) updates recommendations for CCD, formerly known as “stable ischemic heart disease.” This condition encompasses a spectrum of coronary vascular …

Aspirin use for primary prevention among US adults with and without elevated Lipoprotein(a) Open

Alexander C. Razavi, LaTonia C. Richardson, Fátima Coronado, Omar Dzaye, Harpreet Bhatia , et al. · 2024

Cardiovascular Outcomes Among Patients with Acute Coronary Syndromes and Diabetes: Results from ACS QUIK Trial in India Open

Abdulhamied Alfaddagh, Haitham Khraishah, G Romeo, M Kassab, Zeb McMillan , et al. · 2024

Background: Despite cardiovascular disease being the leading cause of death in India, limited data exist regarding the factors associated with outcomes in patients with diabetes who suffer acute myocardial infarction (AMI). Methods: We exa…

Polygenic risk and incident coronary heart disease in a large multiethnic cohort Open

Carlos Iribarren, Meng Lü, Roberto Elosúa, Martha Gulati, Nathan D. Wong , et al. · 2024

Inclusion of polygenic risk improved identification of primary prevention individuals who may benefit from more intensive risk factor modification.

Roger S. Blumenthal YOU? Author Swipe